La cadena de opciones muestra datos clave de las opciones de acciones de Tharimmune a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tharimmune..

Tharimmune (NASDAQ:THAR) Bolsa, Cadena de Opciones

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Neutral and lowers the price target from $124 to $122.

News

Price Target

Analyst Ratings

BNTX

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122

Jan van Eck, CEO of VanEck, focused on two crucial themes during his appearance at the <a href="https://www.benzinga.com/digital-assets">Benzinga&#8217;s Future of Digital Assets Conference</a>: the ambiguity of U.S. fiscal policy and the rapid technological advancements impacting the financial landscape. 
Van Eck&#8217;s remarks provided a nuanced view of how these developments could influence investment strategies and broader financial systems.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42189225/trump-threatens-25-tariffs-on-canada-mexico-until-invasion-is-stopped-but-polymarket-traders-arent-convinced">Trump Threatens Tariffs On Canada, Mexico Until &#8216;Invasion&#8217; Is Stopped, But Polymarket Traders Aren&#8217;t Convinced</a>
<h3 class="wp-block-heading">Unclear Fiscal Priorities Post-Election</h3>
Van Eck addressed the uncertainty surrounding fiscal policy in the wake of recent elections. He noted that, despite a Republican win, the direction of government spending remains undecided. "We have just huge budget deficits in the United States. Any other country doing this stuff would be going bankrupt," he said.
Van Eck outlines the possibilities, which range from maintaining current spending levels to potential budget reductions of up to $500 billion, a concept aligned with proposals from figures like Vivek Ramaswamy. He emphasizes the challenges this ambiguity presents for investors trying to plan for the future.
<h3 class="wp-block-heading">Staying Ahead in a Rapidly Changing Environment</h3>
Touching on technological advancements, van Eck pointed to the rapid evolution of artificial intelligence and its increasing role in financial systems. 
"Change is accelerating," he remarked. For professionals in finance and tech, he said, events like the Benzinga Digital Assets Conference are indispensable for staying informed and connecting with industry leaders. "You almost have to come to events like this to stay on top of it," he added.
The pace of technological transformation, coupled with uncertainty in fiscal policy, underscores the importance of dialogue and collaboration in navigating these challenges. Van Eck's comments reflected the urgency of addressing these shifts to stay competitive.
<h3 class="wp-block-heading">A Balancing Act for the Future</h3>
Van Eck's remarks framed the need to navigate fiscal and technological developments carefully. As the financial world contends with mounting deficits and technological advances, adapting and remaining informed will be critical in shaping strategies and ensuring stability.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs &#8216;As A Weapon&#8217;</a></li>
</ul>
Image: Jan Van Eck/LinkedIn

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

'It's A Problem': VanEck CEO Sounds Off On US Budget Deficits, Rapid Change

Trading Ideas

SMTK

SmartKem Shares Resume Trade

SmartKem Shares Halted On Circuit Breaker To The Downside, Stock Now Up 17.9%

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Outperform and raises the price target from $23 to $28.

Keefe, Bruyette & Woods Maintains Outperform on Old National, Raises Price Target to $28

JP Morgan analyst Rachel Vatnsdal maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Overweight and lowers the price target from $165 to $160.

JP Morgan Maintains Overweight on Agilent Technologies, Lowers Price Target to $160

UAVS

AgEagle Aerial Systems Shares Halted On Circuit Breaker To The Upside, Stock Now Up 28%

Manchester United PLC&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) reported a fiscal first-quarter 2025 sales decline of 8.9% year-on-year to 143.1 million British&nbsp;pounds or $186.07 million, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42185408/manchester-united-plc-reports-first-quarter-fiscal-2025-results" rel="noreferrer noopener">analyst&nbsp;consensus estimate of $194.49 million</a>.
Broadcasting revenue plummeted 20.4%, Commercial revenue fell 5.6%, and Matchday revenue declined 3.3%.
The operating loss for the quarter was (6.9) million pounds compared to 1.9 million pounds profit last year.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" rel="noreferrer noopener">AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market</a>
Adjusted EBITDA was 23.7 million pounds versus 23.3 million pounds last year.
The adjusted loss per share for the period was (0.21) pence versus (5.27) last year. Adjusted EPS loss of $(0.27)&nbsp;beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus loss estimate of $(0.29)</a>.
As of September 30, 2024, the company held 149.6 million pounds in cash and equivalents. The quarter&#8217;s net cash inflow from operating activities was 13.32 million pounds.
As of September 30, 2024, the company&#8217;s USD non-current borrowings were $650 million, unchanged from last year.
CEO Omar Berrada said the men&#8217;s and women&#8217;s seasons are well underway. He acknowledged tapping Ruben Amorim as head coach of the men&#8217;s team. The cost and headcount reductions remain on track. He flagged further commercial traction and welcomed a new partner, Heineken, through their Tiger brand. He added that the renovation of the Carrington Training Centre is progressing well while the Old Trafford Regeneration Task Force continues its work.
Outlook: Manchester United reiterated fiscal 2025 revenue of 650 million pounds-670 million pounds versus&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus of 666.33 million pounds</a>.
It <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40813365/manchester-united-q4-earnings-topline-decline-broadcasting-takes-major-hit-more" rel="noreferrer noopener">maintained a fiscal 2025</a> adjusted EBITDA of 145 million pounds-160 million pounds.
Manchester United stock dropped 15% year-to-date amid reports of a potential full-team sale. In the third quarter of fiscal 2024, the club launched a business transformation plan, appointing new executive leaders, restructuring its organization, and <a target="_blank" href="https://www.benzinga.com//node/40810798" rel="noreferrer noopener">initiating a major cost-cutting program.</a>
Price Action: MANU stock traded lower by 1.98% at $16.87 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42161830/sony-eyes-portable-gaming-market-with-new-handheld-console-in-development" target="_blank" rel="noreferrer noopener">Sony Eyes Portable Gaming Market With New Handheld Console In Development</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Guidance

Sports

Movers

General

MANU

Manchester United Q1 Earnings: Revenue Falls 8.9% As Broadcasting Takes A Hit, Cost Cuts Stay On Track, Reaffirms 2025 Guidance

WIIM

VRME

VerifyMe shares are trading higher after the company announced its board approved a share repurchase plan extension to December 31, 2025.

ZENA

ZenaTech Shares Halted On Circuit Breaker To The Downside, Stock Now Up 63.5%

Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) faced significant service disruptions on Monday with close to 5,400 people reporting issues with Microsoft 365 on the <a href="https://downdetector.com/status/microsoft-365/" target="_blank" rel="noreferrer noopener">Down Detector</a> around noon EST. 
Around 84% of reports stemmed from Outlook, 10% from Exchange, and 6% from Sharepoint.
Close to 8,500 users reported issues with Microsoft Outlook as per <a target="_blank" href="https://downdetector.com/status/outlook/" rel="noreferrer noopener">Down Detector</a>, with 67% of problems corresponding to the website, 22% with the app, and 11% with login issues.
Also Read: <a href="https://www.benzinga.com/24/11/42143717/best-buys-growth-hinges-on-computing-and-services-as-q3-approaches-analyst" target="_blank" rel="noreferrer noopener">Best Buy&#8217;s Growth Hinges On Computing And Services As Q3 Approaches: Analyst</a>
Over 300 users reported issues associated with Microsoft Teams on the <a target="_blank" href="https://downdetector.com/status/teams/" rel="noreferrer noopener">Down Detector</a>, with 61% of the problems related to the server connection, 26% to the website, and 13% to the website.
Microsoft <a href="https://x.com/MSFT365Status/status/1860973220662280356" target="_blank" rel="noreferrer noopener">tweeted</a> at 4:06 am ET that users faced issues with Exchange Online and Microsoft Teams calendars.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We&#39;re investigating an issue impacting users attempting to access Exchange Online or functionality within Microsoft Teams calendar. For more information, please refer to MO941162 in the admin center.
&mdash; Microsoft 365 Status (@MSFT365Status) <a href="https://twitter.com/MSFT365Status/status/1860973220662280356?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
At 9:03 am ET, the company <a target="_blank" href="https://x.com/MSFT365Status/status/1861047970143019048" rel="noreferrer noopener">tweeted</a> that it had deployed a fix progressing through the affected environment. At the same time, it began a manual restart on a subset of affected machines.
At 12:25 pm ET, the company <a target="_blank" href="https://x.com/MSFT365Status/status/1861098870547120306" rel="noreferrer noopener">tweeted</a> that targeted restarts were progressing slower than anticipated for most affected users.
At 5:59 pm ET Tuesday, it <a target="_blank" href="https://x.com/MSFT365Status/status/1861182988022624262" rel="noreferrer noopener">tweeted</a> incremental recovery for some users and focused on additional workstreams to resolve all customers&#8217; issues.
Microsoft&#8217;s <a href="https://admin.microsoft.com/servicestatus" target="_blank" rel="noreferrer noopener">current status</a> says users may be unable to access or use some of Microsoft 365&#8217;s services and features.
OpenAI ChatGPT services also experienced <a href="https://status.openai.com/">disruption on Monday</a>. Users flagged elevated errors on ChatGPT and API from 1:20 pm ET. ChatGPT recovered by 2:55 pm ET, and API performance was recovered for most customers by 4:30 pm ET. The number of issues reported crossed 2,100 on Monday as per <a href="https://downdetector.com/status/openai/">Down Detector</a>.
Price Action: Microsoft stock is down 0.33% at $417.40 premarket at last check Tuesday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42144915/china-unveils-global-ai-governance-committee-with-alibaba-cloud-founder-at-the-helm" target="_blank" rel="noreferrer noopener">China Unveils Global AI Governance Committee With Alibaba Cloud Founder At The Helm</a></li>
</ul>
Image: Shutterstock

Tech

MSFT

Microsoft Service Disruption Hits Outlook And Teams, Thousands Report Issues

WLDS

Wearable Devices shares are trading lower. The company announced it entered into a securities purchase agreement for the sale of 822,000 shares through a registered direct offering priced at $2.25 per unit.

BMO Capital analyst Andrew Strelzik maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Outperform and lowers the price target from $55 to $51.

PLAY

BMO Capital Maintains Outperform on Dave & Buster's Enter, Lowers Price Target to $51

Goldman Sachs analyst Kash Rangan maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral and raises the price target from $72 to $86.

Goldman Sachs Maintains Neutral on Zoom Video Comms, Raises Price Target to $86

<a href="https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan">https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan</a>
&nbsp;
<a href="https://www.aon.com/">Aon plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), a leading global professional services firm, today announced the signing of a definitive agreement to acquire the in-house insurance agency business of Mitsubishi Chemical Group (MCG) enhancing Aon's risk and health capability offering in Japan.
The in-house insurance agency operates as part of Dia Rix, an in-house business services provider to MCG. Aon will acquire the insurance agency business which provides corporate and personal lines insurance to MCG group companies and employees in Japan. The divestiture will allow MCG to divert resources and investment to its core business while leveraging the global risk management capabilities of Aon to strengthen its global governance.
Following the close of the transaction, the team will transition to Aon's brand and operating model, under the leadership of Tatsuya Yamamoto, head of Aon in Japan, bringing together a combined team of more than 400 colleagues.
Anne Corona, CEO for Aon in Asia Pacific said: "This acquisition reinforces our investment in Japan as an important market for Aon. The existing synergies we share with Dia Rix in terms of capability and culture will allow us to better serve MCG as well as strengthen broader capability and development opportunities for colleagues at the combined firm."
Tatsuya Yamamoto added: "The current changes in the non-life insurance environment in Japan will foster an environment in which global companies like the MCG can focus on their core business by divesting their in-house insurance agency operations, while at the same time supporting their operational efficiency strategies and leveraging a group of experts like Aon to provide an opportunity for more sophisticated global risk management. We are well situated to take this business forward building on our existing capabilities and growth momentum and continue to provide optimal solutions for all our clients in Japan."
The firms will continue to operate independently until the transaction is completed, which is expected in early 2025.

Global

Aon To Acquire In-House Insurance Agency Of Mitsubishi Chemical Group In Japan; No Financial Terms Disclosed

Looking into the current session, Hercules Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) shares are trading at $18.86, after a 0.37% decrease. Over the past month, the stock fell by 5.80%, but over the past year, it actually went up by 21.09%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_0.png" alt="Past Year Chart" />

<h3>How Does Hercules Capital P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Hercules Capital has a lower P/E than the aggregate P/E of 24.2 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

HTGC

Price Over Earnings Overview: Hercules Capital

Goldman Sachs analyst Ryan Nash maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and raises the price target from $59 to $67.

ZION

Goldman Sachs Maintains Neutral on Zions Bancorp, Raises Price Target to $67

Goldman Sachs analyst John Mackay maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Neutral and raises the price target from $45 to $55.

Goldman Sachs Maintains Neutral on Williams Companies, Raises Price Target to $55

Macro Economic Events

Econ #s

Economics

S&P/CS HPI Composite - 20 n.s.a. (MoM) For September -0.4% Vs -0.3% Prior

S&P/CS HPI Composite - 20 n.s.a. (YoY) For September 4.6% Vs 4.7% Est.; 5.2% Prior

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is on the move Friday as investors prepare for the company&rsquo;s shares to undergo a reverse split when markets close today.



Tharimmune&nbsp;is enacting a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">one-for-15 reverse stock split</a> for THAR shares. The shares will still trade under the THAR ticker but will switch to the new CUSIP number 432705309.



Tharimmune&nbsp;notes that this split will see it consolidate every 15 shares of its stock into a single share. The company says that this will leave it with 785,978 shares of THAR stock after the reverse split is complete.



<h2>What&rsquo;s Behind the THAR Reverse Stock Split?</h2>



Tharimmune&nbsp;is moving forward with this reverse stock split to boost the price of its shares. The company wants to boost its share price to reach the $1 minimum bid required to remain on The Nasdaq Capital Market. The stock was trading for 33 cents per share when markets closed yesterday.



Tharimmune&nbsp;wants to remain listed as it&rsquo;s still only a clinical-stage biotechnology company. That means it doesn&rsquo;t have a product to sell just yet. Remaining publicly listed is its goal leading up to a potential drug candidate release.



THAR stock is up 3.7% as of Friday morning ahead of the reverse split. However, the company&rsquo;s shares were down 34.5% year-to-date when markets closed on Thursday.



Investors will find more of the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock as well as the biggest pre-market stock movers this morning. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Tharimmune (THAR) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.



SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.



The bad news for Sensei Biotherapeutics comes from its <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">results in this trial</a>. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn&rsquo;t seem to be sitting well with SNSE stockholders today.



Dr.&nbsp;Shiraj Sen, a principal&nbsp;investigator in the SNS-101 study, said the following about the results.




&ldquo;The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn&rsquo;t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.&rdquo;




<h2>SNSE Stock Market Movement on Friday</h2>



SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares of the stock changing hands as of this writing. That&rsquo;s closing in on its daily average trading volume of about 208,000 shares.



SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock, Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>)&nbsp;stock and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock today. All of this info is good to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.



The company is <a href="https://finance.yahoo.com/news/verastem-oncology-announces-positive-initial-210100621.html">conducting a Phase 1/2 clinical trial</a> of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.



However, investors quickly noticed the safety data included in these results. 19 of the 41 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade &ge;3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection, malignant neoplasm progression and vomiting.



John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results.




&ldquo;Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.&rdquo;




<h2>VSTM Stock Movement on Friday</h2>



VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.



VSTM stock is down 61.7% as of Friday morning!



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>), Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock moving today. All of this news is available down below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-verastem-vstm-stock-down-62-today/">Why Is Verastem (VSTM) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Verastem (VSTM) Stock Down 62% Today?

Tharimmune announces $2.08M private placement

Tharimmune files for 1M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the second quarter of 2024.<ul><li>Tharimmune reported earnings per share of -$2.42.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/thar-stock-earnings-tharimmune-for-q2-of-2024/">THAR Stock Earnings: Tharimmune Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

Tharimmune (THAR) presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadel...

Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in ...

Comments

Tharimmune

Tharimmune (THAR) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL